Taking into consideration differences in mTOR pathway alterations between type I endometrial carcinoma and carcinosarcoma, supported by observed in present study resistance of carcinosarcoma cell lines to rapamycin, therefore comparing this studies seems to be doubtful. This evidence concerns the gene MTOR and endometrial carcinoma.